Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?

EP: 1.Optimal Molecular Testing Practices in Non–Small Cell Lung Cancer

EP: 2.Real-World Data and Barriers to Use of Molecular Testing in NSCLC

EP: 3.Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer

EP: 4.Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy

EP: 5.Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy

EP: 6.Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC

EP: 7.Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial

EP: 8.Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS Trials

EP: 9.Neoadjuvant Strategies in Resectable Non–Small Cell Lung Cancer

EP: 10.Selecting Therapy for Advanced NSCLC With EGFR Mutations

Now Viewing

EP: 11.Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?

EP: 12.Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation

EP: 13.Novel Therapy for NSCLC With KRAS G12C Mutation

EP: 14.Novel Therapy for NSCLC With ALK Rearrangements

EP: 15.Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations

EP: 16.Looking Toward the Future Management of Non–Small Cell Lung Cancer

Transcript:

Benjamin Levy, MD: Let’s talk about immunotherapy, specifically single-agent immunotherapy, for EGFR-mutated [lung cancer]. Despite the direct-to-consumer advertising on behalf of immunotherapy companies, these drugs don’t work for everyone, specifically those who have potentially driver mutations. Heather, do you want to briefly walk us through some of the data?

Heather Wakelee, MD: A lot of the data we have are anecdotal. Many of the trials of chemotherapy and immune therapy excluded patients with driver mutations that were known. Many of the driver mutations are in such a small percentage of patients that it’s really hard to have enough data. Stanford [Cancer Institute] was part of the immune targeted analysis where data was gathered from global sites where we had patients with driver mutations who had gotten immune therapy, trying to see if there were signals. From that and from several other similar types of analyses, we know that certain driver mutations like KRAS, beautiful. BRAF was a little bit mixed, we definitely do see some but not everyone, and I think that is because BRAF can happen in people with a smoking history or not. I think with MET it’s also a bit more nuanced. But there are some like ALK, ROS, and RET, where if you find those you know immune therapy is really not going to be working, and you can also have high PD-L1 and it still isn’t going to work.

But there’s more we need to know. I mentioned earlier with the adjuvant immune therapy, this EGFR signal is now seen in both of the trials. That doesn’t make sense, so I think there is more to learn, and especially if immune therapy works, it might be truly curative because you’re teaching the immune system about surveillance. If a TKI [tyrosine kinase inhibitor] works, it might be, but it’s harder to come up with that mechanistically.

Benjamin Levy, MD: All good points, and I think we’ve learned a lot recently about the lack of benefit of some of these drugs, and I think the community and the academics have piled on and said enough is enough. Yes these drugs work, and yes there’s a tail of the curve, and yes patients are being cured, but it’s probably not these patients with EGFR, ALK, or other driver mutations.

Transcript edited for clarity.